Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

ARS Pharmaceuticals (NASDAQ:SPRY) has signed a four-year agreement with ALK-Abelló A/S to co-promote neffy, its epinephrine ...

ARS Pharmaceuticals (NASDAQ:SPRY) partners with ALK to co-promote neffy, an epinephrine nasal spray, to 9,000 pediatricians.

The FDA has approved Atzumi (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults.

SACRAMENTO – Governor Newsom announced that individual twin-packs of CalRx®-branded over-the-counter (OTC) naloxone HCL 4 mg nasal spray are now available to all Californians at a low price of $24 per ...

It’s election this weekend in Australia, and we’re all preparing to dictate what the next three years of our lives will look ...

The US Department of Health and Human Services said Thursday that it aims to accomplish within four years a scientific feat that hasn’t been achieved for the past ...

DHE is a migraine-specific acute medication first approved in 1946. The FDA's approval of the nasal powder formulation, ...

Find out something on the healthier side of smoking. We have some of the herbal options as a healthier alternative to vaping.